↓ Skip to main content

Dove Medical Press

Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First

Overview of attention for article published in Therapeutics and Clinical Risk Management, June 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

twitter
2 X users

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
6 Mendeley
Title
Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First
Published in
Therapeutics and Clinical Risk Management, June 2022
DOI 10.2147/tcrm.s338655
Pubmed ID
Authors

Anagha Deshpande, Javier Munoz

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Other 2 33%
Professor 1 17%
Unknown 3 50%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 1 17%
Agricultural and Biological Sciences 1 17%
Medicine and Dentistry 1 17%
Unknown 3 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2022.
All research outputs
#16,188,873
of 25,584,565 outputs
Outputs from Therapeutics and Clinical Risk Management
#729
of 1,308 outputs
Outputs of similar age
#229,488
of 447,543 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#3
of 13 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 447,543 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.